SCHEMBL26109028

SCHEMBL26109028

COCCc1ccc(OC)c(C=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 1/20 0.48
ALDH1A1 P00352 5/20 0.47
TSHR P16473 3/20 0.47
KDM4E B2RXH2 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
ERN1 O75460 2/20 0.43
FDPS P14324 1/20 0.42
ATM Q13315 2/20 0.42
LMNA P02545 4/20 0.41
MAPT P10636 2/20 0.41
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
POLB P06746 1/20 0.40
CYP19A1 P11511 1/20 0.40
CDK1 P06493 1/20 0.40
CYP2D6 P10635 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PRKDC P78527 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8398420 0.85 TUBB1 (0.49) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL20730189 0.83 ERN1 (0.48) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL19521917 0.83 KDM4E (0.64) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL29119944 0.83 TUBB1 (0.48) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL26107883 0.83 APP (0.44) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL8323669 0.82 PPARG (0.48) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL29951235 0.81 ALDH1A1 (0.52) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL9681414 0.81 ALDH1A1 (0.52) TUBB1ALDH1A1TSHRKDM4ETDP1
SCHEMBL29988598 0.81 CDK1 (0.61) TUBB1ALDH1A1TSHRTDP1ERN1
SCHEMBL13925375 0.81 POLB (0.66) TUBB1ALDH1A1TSHRKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214951-A1 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT VASTHERA CO., LTD. (KR) 2025-07-03 US disclosed
CN-119095831-A 3-Phenylisoxazole derivatives and pharmaceutical compositions for preventing or treating eye diseases containing the same as active ingredient 瓦斯塞拉股份有限公司 2024-12-06 CN disclosed
WO-2023182871-A1 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT 바스테라 주식회사 2023-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214951-A1 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT ATG7, BECN1, MAP1LC3B TUBB1 1190/4885ALDH1A1 336/4885TSHR 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.